REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Price & Overview
NASDAQ:RDHL • US7574683014
The current stock price of RDHL is 0.9455 USD. Today RDHL is up by 0.59%. In the past month the price decreased by -10.38%. In the past year, price decreased by -69.86%.
RDHL Key Statistics
- Market Cap
- 4.834M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.47
- Dividend Yield
- N/A
RDHL Stock Performance
RDHL Stock Chart
RDHL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to RDHL. When comparing the yearly performance of all stocks, RDHL is a bad performer in the overall market: 93.92% of all stocks are doing better.
RDHL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RDHL. RDHL may be in some trouble as it scores bad on both profitability and health.
RDHL Earnings
RDHL Forecast & Estimates
RDHL Groups
Sector & Classification
RDHL Financial Highlights
Over the last trailing twelve months RDHL reported a non-GAAP Earnings per Share(EPS) of -2.47. The EPS decreased by -100.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RDHL Ownership
RDHL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.29 | 948.755B | ||
| JNJ | JOHNSON & JOHNSON | 20.57 | 591.001B | ||
| MRK | MERCK & CO. INC. | 21.45 | 298.537B | ||
| PFE | PFIZER INC | 8.86 | 151.354B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 126.888B | ||
| ZTS | ZOETIS INC | 17.8 | 55.509B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.81 | 27.378B | ||
| VTRS | VIATRIS INC | 5.79 | 16.937B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.74 | 12.151B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.393B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.67B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.517B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 4.459B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RDHL
Company Profile
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Company Info
REDHILL BIOPHARMA LTD-SP ADR
21 Ha'arba'a St.
TEL AVIV-YAFO 64739 IL
CEO: Dror Ben-Asher
Employees: 35
Phone: 97235413131
REDHILL BIOPHARMA LTD-SP ADR / RDHL FAQ
What does RDHL do?
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
What is the stock price of REDHILL BIOPHARMA LTD-SP ADR today?
The current stock price of RDHL is 0.9455 USD. The price increased by 0.59% in the last trading session.
Does REDHILL BIOPHARMA LTD-SP ADR pay dividends?
RDHL does not pay a dividend.
What is the ChartMill technical and fundamental rating of RDHL stock?
RDHL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Short Interest ratio of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?
The outstanding short interest for REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 259.4% of its float.